Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BX002-A · 1 trial · 1 indication
Evaluated by reviewing adverse events
| Arm | Type | Description |
|---|---|---|
| BX002-A | EXPERIMENTAL | BX002-A: 1 mL liquid for multiple dose oral administration |
| Placebo | PLACEBO_COMPARATOR | Placebo: 1 mL liquid for multiple dose oral administration |
| Name | Type | Description |
|---|---|---|
| BX002-A | BIOLOGICAL | bacteriophage cocktail |
| Placebo | OTHER | Placebo |
Inclusion Criteria: 1. Healthy adults 18-65 years old 2. Able to understand study procedures and sign informed consent Exclusion Criteria: 1. Evidence or history of clinically significant underlying conditions 2. Women who are pregnant or nursing, or plan to become pregnant during study, or women...
BX002-A is an investigational monoclonal antibody being developed by BiomX Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific disease indications for BX002-A have not been disclosed.
BX002-A is being developed by BiomX Inc., which trades on the NYSE American under the ticker PHGE. BiomX is the sponsor of the clinical program for this monoclonal antibody candidate.
BX002-A is in Phase 1 development. It has completed one Phase 1 clinical trial, NCT04737876, which evaluated safety, tolerability, and fecal pharmacokinetics in healthy adults. There are currently no active trials of BX002-A.
BX002-A has been studied in one clinical trial: NCT04737876, titled "A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults." This Phase 1 trial was completed, enrolled 18 participants, was randomized and placebo-controlled, and was conducted in the United States.
BX002-A is not approved; it is an investigational monoclonal antibody still in clinical development. Its only completed trial was a Phase 1 study in healthy volunteers, and no active trials are ongoing.